ZDNET’s recommendations are based on thorough testing, research, and comparison shopping to provide accurate information for readers. We gather data from various sources, including vendor listings, independent reviews, and customer feedback. Our goal is to deliver the most knowledgeable advice possible to help you make informed buying decisions.
At CES 2025, two over-the-counter (OTC) continuous glucose monitors (CGM) were announced, offering a potential game-changer in healthcare for individuals with diabetes and insulin-related issues. Abbott’s Lingo and Dexcom’s Stelo are now available for public purchase, providing affordable options for people to track their health.
The Stelo by Dexcom is designed for general wellness tracking but is also suitable for those with Type 2 diabetes who are not on insulin or pre-diabetics aged 18 and above. The device tracks glucose levels 24/7 using a small, flexible wire inserted under the skin. Abbott’s Lingo offers similar features but with a shorter wear span of 14 days.
Both devices offer mobile app connectivity and personalized insights to help users make lifestyle changes. They are available at various pricing tiers: Stelo ($90/month or $100/one-time) and Lingo (2-week plan at $49, 4-week plan at $89, or 12-week subscription at $249).
ZDNET’s editorial team thoroughly reviews and fact-checks every article to ensure accuracy. If you find any inaccuracies, report them through our form. We strive to provide the most accurate information possible to help you make smarter buying decisions.
Source: https://www.zdnet.com/article/two-affordable-otc-continuous-glucose-monitors-won-awards-at-ces-and-you-can-try-them-now